ProCE Banner Activity

Clinical Pearls for the Care of Patients With WM, MCL, HL, and DLBCL

Slideset Download
Highlights in treatment of WM, MCL, HL, and DLBCL from CCO’s coverage of ASCO 2020 and EHA 2020, selected by our expert faculty.

Released: August 31, 2020

Expiration: August 30, 2021

Share

Faculty

John N. Allan

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, New York

Jennifer R. Brown

Jennifer R. Brown, MD, PhD

Assistant Professor of Medicine
Department of Hematologic Malignancies
Dana-Farber Cancer Institute
Harvard Medical School
Attending Physician, Lymphoma Program
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, New York

Jennifer R. Brown, MD, PhD

Assistant Professor of Medicine
Department of Hematologic Malignancies
Dana-Farber Cancer Institute
Harvard Medical School
Attending Physician, Lymphoma Program
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts